Ning Feng, Ye Jin, Wei Li-qiang, Li Xin, Wang Jing-wen
Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Zhonghua Nei Ke Za Zhi. 2012 Oct;51(10):784-7.
To evaluate the clinical features, therapies and prognosis in patients with mucosa-associated lymphoid tissue (MALT) lymphoma in ocular adnexal marginal zone (OAML).
A retrospective analysis was made upon clinical data from 21 patients with OAML admitted into Beijing Tongren Hospital from June, 2008 to December, 2011.
There were 12 (57.1%) men and 9 (42.9%) women, with a median age of 57 (23 - 79) years old. Majority of patients had localized pathological changes. Among them, 16 patients (76.2%) were in stage IE, and 5 (23.8%) in stage IVE. Surgical resection as the sole treatment was performed in 13 patients (61.9%), and positron emission tomography CT(PET-CT) imaging demonstrated normal fluorine 18-fluorodeoxyglucose (FDG) uptake after surgical resection, who were managed with no further therapy. All the 13 patients were followed up for median 14 (5 - 38) months, and all in complete remission. Combination chemotherapy was given to 8 (38.1%) patients. Three patients in stage IE treated with COP (cyclophosphamide, vincristine and prednisone) or CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) were all in partial remission. Five patients in stage IVE were treated with COP/CHOP in combination with rituximab, and all in complete remission. The 3-year overall survival rate and disease-free survival rate in the total patients were 100.0% and 74.9% respectively.
The patients with OAML generally have localized disease, show indolent clinical course, and present low lymphoma-related mortality. Surgical resection is a very important treatment in the patients with local disease. Systemic chemotherapy should be considered in patients at advanced stages. Rituximab in combination with chemotherapy can improve the remission rate.
评估眼附属器边缘区黏膜相关淋巴组织（MALT）淋巴瘤（OAML）患者的临床特征、治疗方法及预后。
回顾性分析2008年6月至2011年12月在北京同仁医院收治的21例OAML患者的临床资料。
男性12例（57.1%），女性9例（42.9%），中位年龄57（23 - 79）岁。多数患者有局限性病变。其中，16例（76.2%）为IE期，5例（23.8%）为IVE期。13例患者（61.9%）仅接受手术切除治疗，术后正电子发射断层扫描CT（PET-CT）成像显示氟代脱氧葡萄糖（FDG）摄取正常，未再接受进一步治疗。13例患者均接受了中位时间为14（5 - 38）个月的随访，均处于完全缓解状态。8例患者（38.1%）接受了联合化疗。3例IE期患者接受环磷酰胺、长春新碱和泼尼松（COP）或环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）方案化疗，均部分缓解。5例IVE期患者接受COP/CHOP联合利妥昔单抗治疗，均完全缓解。全部患者的3年总生存率和无病生存率分别为100.0%和74.9%。
OAML患者通常疾病局限，临床病程惰性，淋巴瘤相关死亡率低。手术切除是局限性疾病患者的重要治疗方法。晚期患者应考虑全身化疗。利妥昔单抗联合化疗可提高缓解率。
